Skip to main content

Table 4 Association of p16 overexpression with various clinical & pathological parameters

From: Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer

 

n (%)

P-Value

Positive (n = 98)

Negative (n = 34)

Focal Positive (n = 5)

Total (n = 137)

Age groups

  ≤ 30 years

3(3.1)

0(0)

0(0)

3(2.2)

0.460

 31–50 years

59(60.2)

16(47.1)

3(60)

78(56.9)

  > 50 years

36(36.7)

18(52.9)

2(40)

56(40.9)

Tumor stage/tumor size

 T1(≤2 cm)

16(16.3)

7(20.6)

1(20)

24(17.5)

0.964

 T2(2.1–5.0 cm)

51(52)

17(50)

3(60)

71(51.8)

 T3(> 5.0 cm)

31(31.6)

10(29.4)

1(20)

42(30.7)

ki67 index groups

  ≤ 15%

10(10.2)

5(14.7)

2(40)

17(12.4)

0.345

 16–24%

5(5.1)

3(8.8)

0(0)

8(5.8)

 25–44%

29(29.6)

11(32.4)

2(40)

42(30.7)

  > 44%

54(55.1)

15(44.1)

1(20)

70(51.1)

Nodal Status

 Positive

42(42.9)

15(44.1)

2(40)

59(43.1)

1.000

 Negative

56(57.1)

19(55.9)

3(60)

78(56.9)

Nodal Stage

 No

58(59.2)

19(55.9)

3(60)

80(58.4)

0.907

 N1

17(17.3)

8(23.5)

2(40)

27(19.7)

 N2

9(9.2)

3(8.8)

0(0)

12(8.8)

 N3

14(14.3)

4(11.8)

0(0)

18(13.1)

Histological Subtypes

 IDC

83(84.7)

28(82.4)

5(100)

116(84.7)

0.633

 Papillary

5(5.1)

0(0)

0(0)

5(3.6)

 Medullary

1(1)

0(0)

0(0)

1(0.7)

 metaplastic

8(8.2)

5(14.7)

0(0)

13(9.5)

 Mixed

1(1)

1(2.9)

0(0)

2(1.5)

Tumor Grade

 Grade-I

0(0)

1(2.9)

0(0)

1(0.7)

0.165

 Grade-II

11(11.2)

7(20.6)

0(0)

18(13.1)

 Grade-III

87(88.8)

26(76.5)

5(100)

118(86.1)

Lymhovascular Invasion

 Present

25(25.5)

6(17.6)

1(20)

32(23.4)

0.788

 Absent

73(74.5)

28(82.4)

4(80)

105(76.6)

Perinodal extension

 Present

19(19.4)

9(26.5)

0(0)

28(20.4)

0.425

 Absent

79(80.6)

25(73.5)

5(100)

109(79.6)

Triple Negative phenotype

 Basal

10(10.2)

3(8.8)

1(20)

14(10.2)

0.532

 Non Basal

88(89.8)

31(91.2)

4(80)

123(89.8)

  1. Chi-Square test applied
  2. P-Value≤0.05, considerd as significant